Search Results
Mar 24, 2026, 08:30 ET IceCure Appoints Meir Peleg as Chief Financial Officer
liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including in the breast, kidney, lung, and liver.ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its
More news about: IceCure Medical
Mar 24, 2026, 08:30 ET HKeyBio Launches HKEY-NHP-onChip™ 1.1: World's First NHP In Vitro Model for Autoimmune and Allergic Diseases
systems simulating intestinal permeability, lung epithelial-immune interactions, and skin microenvironmentNHP co-culture systems integrating immune cells (T cells, B cells, mast cells, myeloid cells) with full tissue reconstruction of skin, lung, and intestinal environmentsDimension
More news about: HKeyBio
Mar 24, 2026, 08:00 ET Optellum AI Shown to be Highly Cost-Effective in First US Lifetime Payer Study of Lung Nodule Risk Stratification
treatment of lung disease, starting with one of the deadliest, lung cancer. Optellum's flagship product, Virtual Nodule Clinic (VNC) with Lung Cancer Prediction AI (LCP), is the world's first and only FDA-cleared and reimbursed software-as-a-medical-device (SaMD) solution for AI-powered lung cancer prioritization
More news about: Optellum
Mar 24, 2026, 03:43 ET DualityBio (9606.HK) Announces 2025 Annual Results
an innovative ADC developed by the Company targeting the HER3 antigen, DB-1310 has achieved important clinical breakthroughs in both Non-Small Cell Lung Cancer ("NSCLC") and breast cancer("BC"), and obtained two Fast Track Designations from the U.S. FDA. In June 2025, the Company presented
More news about: Duality Biotherapeutics, Inc.
Mar 24, 2026, 03:02 ET Fractal's Climate Action Progress Recognized: 2025 [CDP] 'B' Rating Highlights Governance and Measurable Action
Qure.ai, a global healthcare AI leader enhancing the rapid identification and management of tuberculosis, lung cancer, and stroke. Fractal's dedicated AI Research team is focused on foundational AI advancements, including knowledge-based foundational models,
More news about: Fractal Analytics Limited
Mar 24, 2026, 03:00 ET Fractal's Climate Action Progress Recognized: 2025 [CDP] 'B' Rating Highlights Governance and Measurable Action
Qure.ai, a global healthcare AI leader enhancing the rapid identification and management of tuberculosis, lung cancer, and stroke. Fractal's dedicated AI Research team is focused on foundational AI advancements, including knowledge-based foundational models,
More news about: Fractal Analytics Limited
Mar 24, 2026, 01:10 ET Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP
Independent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa ('efti') in patients in 1(st) line non-small cell lung cancer has recommended the discontinuation of the trial following a planned interim futility analysis in accordance with the study protocol." In addition,
More news about: THE ROSEN LAW FIRM, P. A.
Mar 23, 2026, 23:30 ET Prestige Biopharma Announces Positive Topline Results from Comparative SAMSON-II Study for HD204, a Potential Biosimilar to Avastin (bevacizumab)
Primary endpoint of Overall Response Rate at Week 18 met, demonstrating clinical equivalence in patients with advanced non-squamous non-small cell lung cancerSINGAPORE, March 24, 2026 /PRNewswire/ -- Prestige Biopharma
More news about: Prestige Biopharma
Mar 23, 2026, 17:20 ET Pritzker Hageman Representing Woman Sickened in Legionnaires' Disease Outbreak at Rochester Hotel Serving Mayo Clinic Patients
families traveling to Mayo Clinic. The firm's client, 44-year-old Rebecca Lemay of Galesburg, Illinois, traveled to Rochester in January 2025 for lung surgery at Mayo Clinic. She and her husband stayed at the SpringHill Suites, where she used the hotel's spa and pool.Within days of returning
More news about: Pritzker Hageman, P.A.
Mar 23, 2026, 07:46 ET Brayton Purcell LLP Responded Today to New National Reporting by Capital & Main on the Worsening Silicosis Crisis in California
night because I couldn't breathe. I couldn't even take a shower because I would completely run out of air."Oscar ultimately required a double lung transplant in 2024. After the surgery, he told Norris, "Thank God they were able to do the transplant. [But] I imagine it's a process that will never
More news about: Brayton Purcell LLP
Mar 23, 2026, 07:45 ET Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers
treatments in prostate cancer (ZYTIGA®, AKEEGA®, and ERLEDA®), hematologic malignancies (DARZALEX®, CARVYKTI®, TECVAYLI®, TALVEY®, IMBRUVICA®) as well as for lung (RYBREVANT®) and bladder cancer (BALVERSA®). He has been a leader and key participant in four Oncology Drug Advisory Committee (ODAC) presentations,
More news about: TuHURA Biosciences, Inc.
Mar 23, 2026, 07:24 ET Interna Therapeutics Announces Human Challenge Trial Agreement with the University of Oxford to Advance Intranasal MNM-siRNA SARS-CoV-2 Prophylaxis Program
humans.Preclinical studies demonstrated potent antiviral efficacy, favourable safety, and efficient delivery of siRNA into respiratory tracts (nostrils and lung tissue), supporting progressing into clinical efficacy studies.About Interna TherapeuticsInterna Therapeutics is a clinical-stage
More news about: Interna Therapeutics
Mar 23, 2026, 07:00 ET Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease
durable culture conversion at Month 15.About MAC Lung DiseaseMycobacterium avium complex (MAC) lung disease is a rare and serious disease that can significantly increase morbidity and mortality. Patients with MAC lung disease can experience a range of symptoms that often worsen
More news about: Insmed Incorporated
Mar 23, 2026, 05:02 ET Lung Cancer Survivors and Advocates Head to Capitol Hill to Champion Lifesaving Research, Prevention and Access to Care
LUNGFORCE.org.About the American Lung AssociationThe American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research. The work of the American Lung Association is focused on four strategic
More news about: American Lung Association
Mar 23, 2026, 03:00 ET Coreline Soft Supplies Lung Cancer Screening AI to Charité - Universitätsmedizin Berlin
its lung cancer screening (LCS) AI solution to Charité – Universitätsmedizin Berlin, Germany's largest university hospital. This marks the company's entry into a core clinical hub for Germany's National Lung Cancer
More news about: Coreline Soft
Mar 21, 2026, 07:26 ET Dizal Announces Positive Topline Phase 3 Results from WU-KONG28 Study: Evaluating Oral, Once-Daily ZEGFROVY® (Sunvozertinib) vs. Platinum-Containing Chemo Doublet in First-Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutation (exon20ins)
that its multinational Phase 3 WU-KONG28 study evaluating ZEGFROVY® (sunvozertinib) monotherapy as first-line treatment in non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (exon20ins) met its primary endpoint with positive topline results.
More news about: Dizal
Mar 20, 2026, 09:03 ET Henlius Reports 2025 Results: Sustained Growth in Both Revenue and Profit, Advancing Innovation Validation and Global Operations
squamous non-small cell lung cancer (sqNSCLC). It has also been included in public reimbursement systems in seven EU countries, including Germany, Italy, and Spain. To date, serplulimab has been approved in over 40 countries and regions worldwide, with continued progress in lung and gastrointestinal cancers,
More news about: Henlius
Mar 20, 2026, 08:30 ET Caris Life Sciences Announces Another Breakthrough Study for GPSai in Identifying and Correcting Misdiagnosis of Cancer Patients
patients' treatments would achieve better outcomes. According to the CDC website, lung SCC accounts for roughly 21% of all lung cancer cases in the United States. Applying study-specific stats to the wider CDC data for lung cancer in the United States suggests that approximately 1,000 cases each year may
More news about: Caris Life Sciences
Mar 20, 2026, 08:00 ET FIRST ON THE WEST COAST: Eisenhower Lucy Curci Cancer Center Earns Lung Cancer Certification from The Joint Commission
Joint Commission's Gold Seal of Approval® for Lung Cancer Certification — the first on the West Coast — is an important recognition of Eisenhower Lucy Curci Cancer Center's commitment to delivering high-quality, evidence-based care for patients with lung cancer," says Katie Schnaser, Chief Administrative
More news about: Eisenhower Health
Mar 20, 2026, 05:06 ET Antengene Announces 2025 Full-Year Results: First TCE Out-licensing Validates Platform Value and Marks Inflection Point Towards 2026 Profitability
KEYTRUDA® (pembrolizumab) in patients with checkpoint inhibitor (CPI)-resistant melanoma and non-small cell lung cancer (NSCLC). These findings suggest that ATG-037 has clinically meaningful therapeutic potential in multiple tumor types, particularly in patients
More news about: Antengene Corporation Limited
Mar 20, 2026, 00:30 ET AeroDel signs exclusive licensing arrangement with Zydus for launching Aerolife Mini™, India's First Foldable, 'Always Attached' pMDI Enhancer
least one critical error while using inhaler devices, resulting in drug loss and reduced therapeutic benefit.Spacer devices are known to enhance lung deposition of pMDI-delivered drugs by reducing coordination errors. However, this segment remains largely undifferentiated — most existing products
More news about: Aerodel
Mar 19, 2026, 21:00 ET 德昇濟醫藥將於2026年AACR年會展示創新KRAS產品管線，一項摘要入選臨床試驗全體大會口頭報告
Safety and efficacy of Elisrasib (D3S-001), a next generation GDP-bound KRAS G12C inhibitor, as monotherapy in advanced non-small cell lung cancer (NSCLC) previously treated with or without a KRAS G12C inhibitor: Results from a phase 1/2 study 會議名稱：Clinical Trials Plenary 1:
More news about: 德昇濟醫藥（D3 Bio）
Mar 19, 2026, 21:00 ET D3 Bio to Showcase Its Innovative KRAS Pipeline at AACR 2026, Including an Oral Presentation at Clinical Plenary Session
Safety and efficacy of Elisrasib (D3S-001), a next generation GDP-bound KRAS G12C inhibitor, as monotherapy in advanced non-small cell lung cancer (NSCLC) previously treated with or without a KRAS G12C inhibitor: Results from a phase 1/2 studySession Title: Clinical
More news about: D3 Bio
Mar 19, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMP
Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa ('efti') in patients in 1st line non-small cell lung cancer has recommended the discontinuation of the trial following a planned interim futility analysis in accordance with the study protocol." According
More news about: Pomerantz LLP
Mar 19, 2026, 09:44 ET CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026
blood pumps already in the hospital (e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal membrane oxygenation or ECMO, and heart-lung machines), where blood is repeatedly recirculated outside the body, through our cartridges where toxic substances are removed, and then back into the
More news about: Cytosorbents Corp